Network meta-analysis (NMA) of dextromethorphan-bupropion (AXS-05) efficacy and safety in major depressive disorder.

Authors :: Gaca Z
Pruc M
Swieczkowski D
Kwaśny A
Szarpak L
Cubała WJ
Source :: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [Eur Neuropsychopharmacol] 2024 Sep; Vol. 86, pp. 18-19. Date of Electronic Publication: 2024 Jun 24.
Publication Year :: 2024
Abstract: Competing Interests: Declaration of competing interest ZG, MP, DŚ, ŁS: none AK: Grants: Beckley Psytech, GH Research, MSD. WJC: Grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, Beckley Psytech, BMS, Celon, Cephalon, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GH Research, GWPharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, Minerva, MSD, NIH, Novartis, Orion, Otsuka, Sanofi, Servier Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva, Advisory boards: Angelini, Celon (terminated), Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis, Sanofi

Subjects :: Humans
Drug Combinations
Treatment Outcome
Antidepressive Agents, Second-Generation therapeutic use
Antidepressive Agents, Second-Generation adverse effects
Depressive Disorder, Major drug therapy
Dextromethorphan adverse effects
Dextromethorphan therapeutic use
Bupropion therapeutic use
Bupropion adverse effects
Network Meta-Analysis

Language :: English
ISSN :: 1873-7862
Volume :: 86
Database :: MEDLINE
Journal :: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Publication Type :: Report
Accession number :: 38917770
Full Text :: https://doi.org/10.1016/j.euroneuro.2024.04.016

Full Text Access

Tools